In addition, several case studies have reported softening of the skin in SSc patients after the treatment with an anti-IL-6 receptor antibody (tocilizumab), supporting the essential role of IL-6 in the pathogenesis of skin fibrosis associated with SSc24. The gene discussed is IL6; the disease is systemic sclerosis.